Clinical Trial

TARGET 2.0 Study: Safety and Performance of the Cardiovalve TR Replacement System

Recruiting
View on ClinicalTrials.gov →
Summary
This investigation is a continuation for "TARGET" investigation and its purpose is to further demonstrate the efficiency and safety of the Cardiovalve system in the treatment of subjects with tricuspid regurgitation. The same subject population will be included, while applying the clinical and scientific knowledge accumulated in the TARGET investigation. This investigation will support the submission for obtaining marketing approval.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2025-12-31; most recent amendment 2026-05-06.
Status change: Not Yet Recruiting → Recruiting 2026-01-20
Trial Details
NCT Number NCT07334691
Lead Sponsor Cardiovalve Ltd.
Conditions Tricuspid Regurgitation
Enrollment 150 participants
Start Date 2026-01-20
Primary Completion 2028-06 (estimated)
Study Completion 2033-09 (estimated)
Updated on ClinicalTrials.gov 2026-05-11